# Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

> **NCT06690840** · PHASE2 · RECRUITING · sponsor: **European Institute of Oncology** · enrollment: 45 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Atezolizumab in combination with Cyclophosphamide and Vinorelbine

## Key facts

- **NCT ID:** NCT06690840
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-06
- **Primary completion:** 2026-12-15
- **Final completion:** 2027-02-15
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690840, "Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06690840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*